KR20240112931A - 암 치료를 위한 cdk4 억제제 - Google Patents

암 치료를 위한 cdk4 억제제 Download PDF

Info

Publication number
KR20240112931A
KR20240112931A KR1020247021924A KR20247021924A KR20240112931A KR 20240112931 A KR20240112931 A KR 20240112931A KR 1020247021924 A KR1020247021924 A KR 1020247021924A KR 20247021924 A KR20247021924 A KR 20247021924A KR 20240112931 A KR20240112931 A KR 20240112931A
Authority
KR
South Korea
Prior art keywords
cancer
subject
treatment
bid
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247021924A
Other languages
English (en)
Korean (ko)
Inventor
툰 툰 린
징 양
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20240112931A publication Critical patent/KR20240112931A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247021924A 2021-12-02 2022-11-29 암 치료를 위한 cdk4 억제제 Pending KR20240112931A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US63/285,320 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US63/382,346 2022-11-04
US202263383969P 2022-11-16 2022-11-16
US63/383,969 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20240112931A true KR20240112931A (ko) 2024-07-19

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021924A Pending KR20240112931A (ko) 2021-12-02 2022-11-29 암 치료를 위한 cdk4 억제제

Country Status (10)

Country Link
US (1) US20250041298A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542633A (cg-RX-API-DMAC7.html)
KR (1) KR20240112931A (cg-RX-API-DMAC7.html)
AU (1) AU2022400308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240993A1 (cg-RX-API-DMAC7.html)
IL (1) IL312650A (cg-RX-API-DMAC7.html)
MX (1) MX2024006678A (cg-RX-API-DMAC7.html)
TW (1) TWI922768B (cg-RX-API-DMAC7.html)
WO (1) WO2023100070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
MX2023003054A (es) * 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth

Also Published As

Publication number Publication date
MX2024006678A (es) 2024-06-19
IL312650A (en) 2024-07-01
AU2022400308B2 (en) 2026-02-12
JP2024542633A (ja) 2024-11-15
EP4440576A1 (en) 2024-10-09
TWI922768B (zh) 2026-04-21
AU2022400308A1 (en) 2024-05-16
CA3240993A1 (en) 2023-06-08
TW202329970A (zh) 2023-08-01
WO2023100070A1 (en) 2023-06-08
US20250041298A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
JP2024001009A (ja) Pi3k阻害剤であるgdc-0077による癌の治療方法
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
AU2013299841B2 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
RS57275B1 (sr) Tretman gihta i hiperurikemije
WO2022218958A1 (en) Combination comprising everolimus and amcenestrant
AU2021382148A9 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2022544485A (ja) Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
JP2025509278A (ja) 小細胞肺癌を治療する方法
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
KR20210121188A (ko) 아나스트로졸과 조합된 cdk4/6 억제제를 함유하는 조성물의 종양 질환 치료용 약제의 제조에서의 용도
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
EP4704847A1 (en) Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
HK40066922A (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902